Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder
PV Magalhaes, OM Dean, AI Bush, DL Copolov, D Weisinger, GS Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk
Progress in Neuro-Psychopharmacology and Biological Psychiatry | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2012
This trial was supported by a grant from the Stanley Medical Research Institute, as well as the Mental Health Research Institute of Victoria. Trial registration: Australian Clinical Trials Registry 12605000362695, www.actr.org.au.Dr. Magalhaes is supported by a split doctoral scholarship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.Prof. Malhi has served on a number of international and national pharmaceutical advisory boards, received funding for research and has been in receipt of honoraria for talks at sponsored meetings worldwide involving the following companies: Astra Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Organon, Pfizer, Ranbaxy, Servier and Wyeth.Prof. Berk has received research support from: Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier. He has been a speaker for Speaker: Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, Wyeth. He has been a consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier.